The potent human immunodeficiency virus type 1 (HIV-1) entry inhibitor HR212 blocks formation of the envelope glycoprotein gp41 six-Helix bundle

AIDS Research and Human Retroviruses

Volumn 29, Issue 3, 2013, Pages 613-620

  Ouyang, Wenjie ^a   An, Tai ^a   Guo, Deyin ^a   Wu, Shuwen ^a   Tien, Po ^a,b  

^a WUHAN UNIVERSITY   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 41; HR 212; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; FLUORESCENCE ANALYSIS; NATIVE POLYACRYLAMIDE GEL ELECTROPHORESIS; NONHUMAN; PRIORITY JOURNAL;

ELECTROPHORESIS, POLYACRYLAMIDE GEL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; PROTEIN BINDING; PROTEIN FOLDING;

EID: 84874502331     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0059     Document Type: Article

References (34)

1. Pan C, Liu S, and Jiang S: HIV-1 gp41 fusion intermediate: A target for HIV therapeutics. J Formos Med Assoc 2010; 109(2):94-105.
2. Doms RW and Moore JP: HIV-1 membrane fusion: Targets of opportunity. J Cell Biol 2000;151(2):F9-14.
3. He Y, Xiao Y, Song H, et al.: Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008; 283(17):11126-11134.
4. Moore JP and Doms RW: The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci USA 2003;100(19):10598-10602.
5. Wyatt R and Sodroski J: The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998; 280(5371):1884-1888.
6. Chan DC and Kim PS: HIV entry and its inhibition. Cell 1998;93(5):681-684.
7. Melikyan GB, Markosyan RM, Hemmati H, et al.: Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000;151(2):413-423.
8. Liu S, Wu S, and Jiang S: HIV entry inhibitors targeting gp41: From polypeptides to small-molecule compounds. Curr Pharm Des 2007;13(2):143-162.
9. He Y, Cheng J, Lu H, et al.: Potent HIV fusion inhibitors against enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci USA 2008;105(42):16332- 16337.
10. Tashima KT and Carpenter CC: Fusion inhibition - a major but costly step forward in the treatment of HIV-1. N Engl J Med 2003;348(22):2249-2250.
11. Ni L, Gao GF, and Tien P: Rational design of highly potent HIV-1 fusion inhibitory proteins: Implication for developing antiviral therapeutics. Biochem Biophys Res Commun 2005; 332(3):831-836.
12. Pang W, Wang RR, Yang LM, et al.: Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro. Virology 2008;377(1):80-87.
13. Louis JM, Bewley CA, and Clore GM: Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem 2001;276(31): 29485-29489.
14. Deng Y, Zheng Q, Ketas TJ, et al.: Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry 2007;46(14):4360-4369.
15. Liu JJ, Reid G, Jiang Y, et al.: Activity of HIV entry and fusion inhibitors expressed by the human vaginal colonizing probiotic Lactobacillus reuteri RC-14. Cell Microbiol 2007; 9(1):120-130.
16. Huang JH, Yang HW, Liu S, et al.: The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation. Biochem J 2007;403(3):565-571.
17. Jiang S, Lu H, Liu S, et al.: N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother 2004;48(11):4349-4359.
18. Wang H, Qi Z, Guo A, et al.: ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-Active gp41 core formation. Antimicrob Agents Chemother 2009;53(12):4987-4998.
19. Liu S, Lu H, Niu J, et al.: Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005;280(12):11259-11273.
20. Zhao Q, Ernst JT, Hamilton AD, et al.: XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res Hum Retroviruses 2002;18(14):989-997.
21. Zhao Q, He Y, Alespeiti G, and Debnath AK: A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5. Virology 2004;326(2):299-309.
22. Dorr P, Westby M, Dobbs S, et al.: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49(11):4721-4732.
23. Liu S, Zhao Q, and Jiang S: Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: Applicable for identification of HIV-1 fusion inhibitors. Peptides 2003;24(9):1303-1313.
24. Jiang S, Lin K, Zhang L, and Debnath AK: A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation- specific monoclonal antibody. J Virol Methods 1999;80(1):85-96.
25. Lu M, Blacklow SC, and Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2(12):1075-1082.
26. Schols D, Este JA, Henson G, and De Clercq E: Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997;35(3):147-156.
27. Jiang S, Lin K, and Lu M: A conformation-specific monoclonal antibody reacting with fusion-Active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1998;72(12):10213-10217.
28. Oldfield V, Keating GM, and Plosker G: Enfuvirtide: A review of its use in the management of HIV infection. Drugs 2005;65(8):1139-1160.
29. Peuchant O, Capdepont S, Ragnaud JM, et al.: Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort. Antivir Ther 2007;12(4):559-562.
30. Liu S, Jing W, Cheung B, et al.: HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem 2007; 282(13):9612-9620.
31. Naito T, Izumi K, Kodama E, et al.: SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob Agents Chemother 2009;53(3):1013-1018.
32. Dwyer JJ, Wilson KL, Davison DK, et al.: Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA 2007;104(31):12772-12777.
33. Miyauchi K, Kim Y, Latinovic O, et al.: HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009;137(3):433-444.
34. Veazey RS, Klasse PJ, Schader SM, et al.: Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005;438(7064): 99-102.